A detailed history of Royal Bank Of Canada transactions in Uni Qure N.V. stock. As of the latest transaction made, Royal Bank Of Canada holds 77,108 shares of QURE stock, worth $495,033. This represents 0.0% of its overall portfolio holdings.

Number of Shares
77,108
Previous 53,683 43.64%
Holding current value
$495,033
Previous $279,000 23.66%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$4.39 - $5.43 $102,835 - $127,197
23,425 Added 43.64%
77,108 $345,000
Q1 2024

May 15, 2024

SELL
$4.82 - $6.93 $128,163 - $184,268
-26,590 Reduced 33.12%
53,683 $279,000
Q4 2023

Feb 14, 2024

BUY
$5.63 - $8.27 $71,743 - $105,384
12,743 Added 18.87%
80,273 $543,000
Q3 2023

Nov 14, 2023

BUY
$6.71 - $11.83 $30,476 - $53,731
4,542 Added 7.21%
67,530 $453,000
Q2 2023

Aug 14, 2023

BUY
$11.12 - $22.2 $55,688 - $111,177
5,008 Added 8.64%
62,988 $721,000
Q1 2023

May 15, 2023

SELL
$18.7 - $23.07 $67,076 - $82,752
-3,587 Reduced 5.83%
57,980 $1.17 Million
Q4 2022

Feb 14, 2023

SELL
$18.12 - $27.32 $153,023 - $230,717
-8,445 Reduced 12.06%
61,567 $1.4 Million
Q3 2022

Nov 14, 2022

SELL
$16.98 - $25.54 $23,415 - $35,219
-1,379 Reduced 1.93%
70,012 $1.31 Million
Q2 2022

Aug 15, 2022

SELL
$13.15 - $20.45 $44,433 - $69,100
-3,379 Reduced 4.52%
71,391 $1.33 Million
Q1 2022

May 16, 2022

BUY
$14.54 - $21.5 $77,469 - $114,552
5,328 Added 7.67%
74,770 $1.35 Million
Q4 2021

Feb 14, 2022

SELL
$20.24 - $36.01 $50,863 - $90,493
-2,513 Reduced 3.49%
69,442 $1.44 Million
Q3 2021

Nov 15, 2021

SELL
$26.01 - $38.22 $136,552 - $200,655
-5,250 Reduced 6.8%
71,955 $2.3 Million
Q2 2021

Aug 16, 2021

BUY
$29.97 - $37.17 $2.31 Million - $2.87 Million
77,205 New
77,205 $2.38 Million

Others Institutions Holding QURE

About uniQure N.V.


  • Ticker QURE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,729,100
  • Market Cap $300M
  • Description
  • uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...
More about QURE
Track This Portfolio

Track Royal Bank Of Canada Portfolio

Follow Royal Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.